No abstract available.
Red-Cell Aplasia, Pure*

No abstract available.
Red-Cell Aplasia, Pure* ; Rituximab*

Humans ; Red-Cell Aplasia, Pure

No abstract available.
Myelodysplastic Syndromes* ; Red-Cell Aplasia, Pure*

Thymoma, a rare epithelial neoplasm, is the most common anterior-superior mediastinal tumour. Thymoma can occur sporadically or in association with other conditions, such as myasthenia gravis, pure red cell aplasia (PRCA), and hypogammaglobulinemia. Only 5% of thymoma cases develop PRCA; however, 10–50% of patients presenting with PRCA have an associated spindle cell type thymoma. Thymoma complicated by PRCA is associated with a poor outcome. We report the case of a 38-year-old female who presented with chest pain, and was diagnosed with an anterior mediastinal mass. A thymectomy was performed, and histopathological examination revealed mixed thymoma; two months later, the patient developed PRCA. The present case reinforces the need for clinicians to be vigilant with thymoma patients, even following thymectomy.
Erythropoiesis ; Mediastinum ; Red-Cell Aplasia, Pure ; Thymoma

Consensus ; Humans ; Red-Cell Aplasia, Pure

The authors have described a case with pure red cell aplasia (P.R.C.A.) caused by the administration of diphenylhydantoin after head injury. P.R.C.A. associated with diphenylhydantoin is very rare and easily treated with a discontinuation of diphenylhydantoin & steroids.
Craniocerebral Trauma ; Phenytoin* ; Red-Cell Aplasia, Pure* ; Steroids

Humans ; Anemia, Aplastic/genetics* ; Red-Cell Aplasia, Pure ; Chromosome Disorders

Recombinant human erythropoietin (rHuEPO) is extensively used in anemic patients on dialysis. We experienced a case of pure red-cell aplasia (PRCA) caused by anti-rHuEPO Antibody. A 48-year-old male with CRF was placed on chronic hemodialysis. He developed severe anemia (Hb 6.6 g/dL) without any apparent blood loss. A transfusion was given and the rHuEPO dose was increased to 12, 000 U/week SC. A bone marrow study was carried out. Anti-rHuEPO antibodies were positive. rHuEPO therapy was stopped. No improvement in the anemia was apparent. Although very rare, anti-rHuEPO antibodies should be evaluated in patients with severe anemia without obvious etiology.
Anemia ; Antibodies* ; Bone Marrow ; Dialysis ; Erythropoietin* ; Humans ; Male ; Middle Aged ; Red-Cell Aplasia, Pure* ; Renal Dialysis

Patients with erythropoiesis-stimulating agent (ESA)-induced pure red cell aplasia (PRCA) should not routinely be switched to an alternative ESA or to darbepoetin-alpha because anti-erythropoietin (anti-EPO) antibodies cross-react with all kinds of recombinant ESAs. We present a case of ESA-induced PRCA in a 69-year-old man on hemodialysis whose anemia improved with reintroduction of darbepoetin-alpha following immunosuppressive therapy. The patient developed severe anemia after 15 months of subcutaneous administration of erythropoietin-alpha. After the diagnosis of PRCA, erythropoietin-alpha was discontinued and immunosuppressive therapy with a combination of prednisolone and oral cyclophosphamide was initiated. After 4 months of immunosuppressive therapy, the anti-EPO antibody titer was markedly decreased; however, esophageal candidiasis developed. Additional therapy with cyclosporine alone instead of prednisone and cyclophosphamide was performed, and anti-EPO antibody was subsequently not detected. Darbepoetin-alpha was then reintroduced, and the patient's anemia improved without red cell transfusion. In conclusion, ESA-induced PRCA was successfully treated with reintroduction of darbepoetin-alpha following immunosuppressive therapy.
Anemia ; Antibodies ; Candidiasis ; Cyclophosphamide ; Cyclosporine ; Dialysis ; Erythropoietin ; Humans ; Prednisolone ; Prednisone ; Red-Cell Aplasia, Pure ; Renal Dialysis